Case report Open Access Logo

Umbilical cord derived stem cell (ModulatistTM) transplantation for severe chronic obstructive pulmonary disease: a report of two cases

Phuong Thi-Bich Le 1
Tuan Minh Duong 1
Ngoc Bich Vu 2
Phuc Van Pham 2, * ORCID logo
  1. Stem Cell Unit, Van Hanh Hospital, Ho Chi Minh city, Viet Nam
  2. Laboratory of Stem Cell Research and Application, University of Science, Vietnam National University, Ho Chi Minh city, Viet Nam
Correspondence to: Phuc Van Pham, Laboratory of Stem Cell Research and Application, University of Science, Vietnam National University, Ho Chi Minh city, Viet Nam. ORCID: http://orcid.org/0000-0001-7254-0717. Email: [email protected].
Volume & Issue: Vol. 3 No. 10 (2016) | Page No.: 902-909 |
Published: 2016-10-29

Online metrics


Statistics from the website

  • HTML Views: 6629
  • PDF Views: 2122
  • XML Views: 38

Statistics from Dimensions

Statistics from PlumX

Copyright The Author(s) 2024. This article is published with open access by BioMedPress. This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. 

Abstract

Introduction: Chronic obstructive pulmonary disease (COPD) is a chronic disease affecting the airway of the respiratory system. COPD cases have rapidly increased in recent years, with the disease becoming the fourth leading cause of death worldwide. Stem cell transplantation is a new approach to treat COPD. In this study we report in two cases the use of transplanted stem cells to treat COPD.

Methods: Umbilical cord derived stem cells (ModulatistTM) were used in the study. ModulatistTM was prepared according to previous published studies. Two patients with late stage COPD (stage IV) were transfused with Modulatist at a dose of 106 cells/kg. Patients were evaluated by the COPD assessment test (CAT) score as well as the Modified Medical Research Council Dyspnea Scale (mMRC) score, before and after transplantation (1, 3 and 5 months post transplantation).

Results: Results showed that ModulatistTM transplantation significantly improved sever COPD, especially after 3 months. At that time point, the two patients receiving ModulatistTM showed a significantly improvement, from late-stage of COPD (stage IV) to stage I.

Conclusion: Although these initial results suggest that ModulatistTM transplantation is a promising therapy, more clinical studies in COPD patients are warranted to evaluate efficacy. 

Sorry, we can not display full-text of this article in HTML format for you right now. Please get the article in PDF format instead.

Comments